DQB1*0602 predicts interindividual differences in physiologic sleep, sleepiness, and fatigue
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: The human leukocyte antigen (HLA) DQB1*0602 allele is closely associated with narcolepsy, a neurologic disorder characterized by excessive daytime sleepiness, fragmented sleep, and shortened REM sleep latency. We evaluated whether DQB1*0602 was a novel marker of interindividual differences by determining its relationship to sleep homeostatic, sleepiness, and cognitive responses to baseline and chronic partial sleep deprivation (PSD) conditions.
Methods: Ninety-two DQB1*0602-negative and 37 DQB1*0602-positive healthy adults participated in a protocol of 2 baseline 10 hours time in bed (TIB) nights followed by 5 consecutive 4 hours TIB nights. DQB1*0602 allelic frequencies did not differ significantly between Caucasians and African Americans.
Results: During baseline, although DQB1*0602-positive subjects were subjectively sleepier and more fatigued, they showed greater sleep fragmentation, and decreased sleep homeostatic pressure and differentially sharper declines during the night (measured by non-REM EEG slow-wave energy [SWE]). During PSD, DQB1*0602-positive subjects were sleepier and showed more fragmented sleep, despite SWE elevation comparable to negative subjects. Moreover, they showed differentially greater REM sleep latency reductions and smaller stage 2 reductions, along with differentially greater increases in fatigue. Both groups demonstrated comparable cumulative decreases in cognitive performance.
Conclusions: DQB1*0602 positivity in a healthy population may represent a continuum of some sleep–wake features of narcolepsy. DQB1*0602 was associated with interindividual differences in sleep homeostasis, physiologic sleep, sleepiness, and fatigue—but not in cognitive measures—during baseline and chronic PSD. Thus, DQB1*0602 may represent a genetic biomarker for predicting such individual differences in basal and sleep loss conditions.
Footnotes
Study funding: Supported by the National Space Biomedical Research Institute through NASA (NCC 9-58), NIH NR004281, and CTRC UL1RR024134 (to D.F.D.), the NIH (NS-23724 to E.M.), the Institute for Translational Medicine and Therapeutics' (ITMAT) Transdisciplinary Program in Translational Medicine and Therapeutics (to N.G.), and the National Center for Research Resources (UL1RR024134). E.M. is a Howard Hughes Medical Institute Investigator.
Editorial, page 1492
Supplemental data at www.neurology.org.
References e1–e12 are available on the Neurology Web site at www.neurology.org.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.
-
- ANOVA
- analysis of variance
- COWAT
- Controlled Oral Word Association Test
- DS
- Digit Span
- DSST
- Digit Symbol Substitution Task
- HLA
- human leukocyte antigen
- KSS
- Karolinska Sleepiness Scale
- MWT
- Maintenance of Wakefulness Test
- POMS
- Profile of Mood States
- PSD
- partial sleep deprivation
- PSG
- polysomnography
- PVT
- Psychomotor Vigilance Task
- SOL
- sleep onset latency
- SR
- sleep deprivation/restriction
- SWA
- slow-wave activity
- SWE
- slow-wave energy
- TIB
- time in bed
- TOL
- Tower of London
- TSD
- total sleep deprivation
- VAS
- visual analog scale
- WASO
- wake after sleep onset.
- Received December 29, 2009.
- Accepted June 14, 2010.
- Copyright © 2010 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Jessica Ailani and Dr. Ailna Masters-Israilov
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Objective daytime sleepiness in patients with somnambulism or sleep terrorsRégis Lopez, Isabelle Jaussent, Yves Dauvilliers et al.Neurology, October 29, 2014 -
Articles
Effect of age on MSLT results in patients with narcolepsy–cataplexyY. Dauvilliers, A. Gosselin, J. Paquet et al.Neurology, January 12, 2004 -
Articles
The hypocretin neurotransmission system in myotonic dystrophy type 1E. Ciafaloni, E. Mignot, V. Sansone et al.Neurology, January 14, 2008 -
Article
Sleep–wake disorders persist 18 months after traumatic brain injury but remain underrecognizedLukas L. Imbach, Fabian Büchele, Philipp O. Valko et al.Neurology, April 27, 2016